Clinical trial NCT03328845 - References

Type 1 Diabetes Mellitus — Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)

Citation(s)

•   Aljada A, Ghanim H, Saadeh R, Dandona P
  Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab. 2001 Jan;86(1):450-3.
•   Arufe MC, Lu M, Lin RY
  Differentiation of murine embryonic stem cells to thyrocytes requires insulin and insulin-like growth factor-1. Biochem Biophys Res Commun. 2009 Apr 3;381(2):264-70. doi: 10.1016/j.bbrc.2009.02.035. Epub 2009 Feb 14.
•   Bashan N, Kovsan J, Kachko I, Ovadia H, Rudich A
  Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiol Rev. 2009 Jan;89(1):27-71. doi: 10.1152/physrev.00014.2008. Review.
•   Baynes JW, Thorpe SR
  Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999 Jan;48(1):1-9. Review.
•   Baynes JW
  Role of oxidative stress in development of complications in diabetes. Diabetes. 1991 Apr;40(4):405-12. Review.
•   Berg TJ, Nourooz-Zadeh J, Wolff SP, Tritschler HJ, Bangstad HJ, Hanssen KF
  Hydroperoxides in plasma are reduced by intensified insulin treatment. A randomized controlled study of IDDM patients with microalbuminuria. Diabetes Care. 1998 Aug;21(8):1295-300.
•   Bergenstal RM, Bailey TS, Rodbard D, Ziemen M, Guo H, Muehlen-Bartmer I, Ahmann AJ
  Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections. Diabetes Care. 2017 Apr;40(4):554-560. doi: 10.2337/dc16-0684. Epub 2017 Jan 23.
•   Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR; BEGIN® Basal-Bolus Type 1 trial investigators
  Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med. 2013 Nov;30(11):1293-7. doi: 10.1111/dme.12243. Epub 2013 Jun 17.
•   Bravi MC, Armiento A, Laurenti O, Cassone-Faldetta M, De Luca O, Moretti A, De Mattia G
  Insulin decreases intracellular oxidative stress in patients with type 2 diabetes mellitus. Metabolism. 2006 May;55(5):691-5.
•   Brownlee M
  The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005 Jun;54(6):1615-25.
•   Ceolotto G, Bevilacqua M, Papparella I, Baritono E, Franco L, Corvaja C, Mazzoni M, Semplicini A, Avogaro A
  Insulin generates free radicals by an NAD(P)H, phosphatidylinositol 3'-kinase-dependent mechanism in human skin fibroblasts ex vivo. Diabetes. 2004 May;53(5):1344-51.
•   Ceriello A, Esposito K, Ihnat M, Thorpe J, Giugliano D
  Effect of acute hyperglycaemia, long-term glycaemic control and insulin on endothelial dysfunction and inflammation in Type 1 diabetic patients with different characteristics. Diabet Med. 2010 Aug;27(8):911-7. doi: 10.1111/j.1464-5491.2009.02928.x.
•   Ceriello A, Ihnat M
  Oxidative stress is, convincingly, the mediator of the dangerous effects of glucose variability. Diabet Med. 2010 Aug;27(8):968. doi: 10.1111/j.1464-5491.2010.02931.x.
•   Ceriello A, Novials A, Ortega E, Canivell S, La Sala L, Pujadas G, Esposito K, Giugliano D, Genovese S
  Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care. 2013 Aug;36(8):2346-50. doi: 10.2337/dc12-2469. Epub 2013 Apr 5.
•   Ceriello A
  Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes. Eur J Cardiovasc Prev Rehabil. 2010 May;17 Suppl 1:S15-9. doi: 10.1097/01.hjr.0000368193.24732.66. Review.
•   Chang L, Chiang SH, Saltiel AR
  Insulin signaling and the regulation of glucose transport. Mol Med. 2004 Jul-Dec;10(7-12):65-71. Review.
•   Costacou T, Evans RW, Schafer GL, Orchard TJ
  Oxidative stress and response in relation to coronary artery disease in type 1 diabetes. Diabetes Care. 2013 Nov;36(11):3503-9. doi: 10.2337/dc12-2378. Epub 2013 Aug 6.
•   Costacou T, Lopes-Virella MF, Zgibor JC, Virella G, Otvos J, Walsh M, Orchard TJ
  Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. J Diabetes Complications. 2005 Jul-Aug;19(4):183-93.
•   Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S
  Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab. 2001 Jul;86(7):3257-65.
•   Dandona P, Chaudhuri A, Ghanim H, Mohanty P
  Effect of hyperglycemia and insulin in acute coronary syndromes. Am J Cardiol. 2007 Jun 4;99(11A):12H-18H. Review.
•   Dandona P, Chaudhuri A, Ghanim H, Mohanty P
  Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol. 2009 Feb 3;53(5 Suppl):S14-20. doi: 10.1016/j.jacc.2008.10.038. Review.
•   Davies MJ, Derezinski T, Pedersen CB, Clauson P
  Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technol Ther. 2008 Aug;10(4):273-7. doi: 10.1089/dia.2008.0282.
•   Delmastro MM, Piganelli JD
  Oxidative stress and redox modulation potential in type 1 diabetes. Clin Dev Immunol. 2011;2011:593863. doi: 10.1155/2011/593863. Epub 2011 May 18.
•   Domínguez C, Ruiz E, Gussinye M, Carrascosa A
  Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents. Diabetes Care. 1998 Oct;21(10):1736-42.
•   Fawcett J, Tsui BT, Kruer MC, Duckworth WC
  Reduced action of insulin glargine on protein and lipid metabolism: possible relationship to cellular hormone metabolism. Metabolism. 2004 Aug;53(8):1037-44.
•   Francescato MP, Stel G, Geat M, Cauci S
  Oxidative stress in patients with type 1 diabetes mellitus: is it affected by a single bout of prolonged exercise? PLoS One. 2014 Jun 6;9(6):e99062. doi: 10.1371/journal.pone.0099062. eCollection 2014.
•   Franklin VL, Khan F, Kennedy G, Belch JJ, Greene SA
  Intensive insulin therapy improves endothelial function and microvascular reactivity in young people with type 1 diabetes. Diabetologia. 2008 Feb;51(2):353-60. Epub 2007 Nov 27.
•   García-Escobar E, Rodríguez-Pacheco F, Haro-Mora JJ, Gomez-Zumaquero JM, Rubio-Martín E, Gutierrez-Repiso C, Soriguer F, Rojo-Martínez G
  Effect of insulin analogues on 3t3-l1 adipogenesis and lipolysis. Eur J Clin Invest. 2011 Sep;41(9):979-86. doi: 10.1111/j.1365-2362.2011.02492.x. Epub 2011 Mar 2.
•   Giacco F, Brownlee M
  Oxidative stress and diabetic complications. Circ Res. 2010 Oct 29;107(9):1058-70. doi: 10.1161/CIRCRESAHA.110.223545. Review.
•   Goldman J, White JR Jr
  New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus. Ann Pharmacother. 2015 Oct;49(10):1153-61. doi: 10.1177/1060028015597915. Epub 2015 Aug 3. Review.
•   Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T
  Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000 May;23(5):644-9.
•   Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H
  Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012 Sep;14(9):859-64. doi: 10.1111/j.1463-1326.2012.01627.x. Epub 2012 Jun 7.
•   Hoeldtke RD, Bryner KD, Hoeldtke ME, Christie I, Ganser G, Hobbs G, Riggs J
  Sympathetic sudomotor disturbance in early type 1 diabetes mellitus is linked to lipid peroxidation. Metabolism. 2006 Nov;55(11):1524-31.
•   Højlund K, Poulsen M, Staehr P, Brusgaard K, Beck-Nielsen H
  Effect of insulin on protein phosphatase 2A expression in muscle in type 2 diabetes. Eur J Clin Invest. 2002 Dec;32(12):918-23.
•   Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, Riddle MC
  New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care. 2015 Dec;38(12):2217-25. doi: 10.2337/dc15-0249. Epub 2015 Jun 17.
•   Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G
  Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care. 2003 Jul;26(7):2027-31.
•   Järvisalo MJ, Raitakari M, Toikka JO, Putto-Laurila A, Rontu R, Laine S, Lehtimäki T, Rönnemaa T, Viikari J, Raitakari OT
  Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. Circulation. 2004 Apr 13;109(14):1750-5. Epub 2004 Mar 15.
•   Kalra S, Baruah MP, Niazi AK
  Degludec: a novel basal insulin. Recent Pat Endocr Metab Immune Drug Discov. 2012 Jan;6(1):18-23. Review.
•   Korytkowski MT, Salata RJ, Koerbel GL, Selzer F, Karslioglu E, Idriss AM, Lee KK, Moser AJ, Toledo FG
  Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial. Diabetes Care. 2009 Apr;32(4):594-6. doi: 10.2337/dc08-1436.
•   Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C, Trüb T
  Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000 Jun;49(6):999-1005.
•   Laaksonen DE, Atalay M, Niskanen L, Uusitupa M, Hänninen O, Sen CK
  Increased resting and exercise-induced oxidative stress in young IDDM men. Diabetes Care. 1996 Jun;19(6):569-74.
•   Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB
  Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000 Dec;49(12):2142-8.
•   Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B; PREFER Study Group
  Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab. 2009 Jan;11(1):45-52. doi: 10.1111/j.1463-1326.2008.00915.x. Epub 2008 Jul 17.
•   Liu HY, Cao SY, Hong T, Han J, Liu Z, Cao W
  Insulin is a stronger inducer of insulin resistance than hyperglycemia in mice with type 1 diabetes mellitus (T1DM). J Biol Chem. 2009 Oct 2;284(40):27090-100. doi: 10.1074/jbc.M109.016675. Epub 2009 Aug 4.
•   Mäkimattila S, Virkamäki A, Malmström R, Utriainen T, Yki-Jarvinen H
  Insulin resistance in type I diabetes mellitus: a major role for reduced glucose extraction. J Clin Endocrinol Metab. 1996 Feb;81(2):707-12.
•   Mannucci E, Monami M, Marchionni N
  Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. Diabetes Obes Metab. 2009 Jan;11(1):53-9. doi: 10.1111/j.1463-1326.2008.00934.x. Epub 2008 Jul 29. Review.
•   Marra G, Cotroneo P, Pitocco D, Manto A, Di Leo MA, Ruotolo V, Caputo S, Giardina B, Ghirlanda G, Santini SA
  Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes: a case for gender difference. Diabetes Care. 2002 Feb;25(2):370-5.
•   Matsuhisa M, Koyama M, Cheng X, Sumi M, Riddle MC, Bolli GB, Hirose T; EDITION JP 1 study group
  Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension). Diabetes Res Clin Pract. 2016 Dec;122:133-140. doi: 10.1016/j.diabres.2016.10.002. Epub 2016 Oct 13.
•   Monnier L, Colette C, Mas E, Michel F, Cristol JP, Boegner C, Owens DR
  Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia. 2010 Mar;53(3):562-71. doi: 10.1007/s00125-009-1574-6. Epub 2009 Nov 5.
•   Monnier L, Hanefeld M, Schnell O, Colette C, Owens D
  Insulin and atherosclerosis: how are they related? Diabetes Metab. 2013 Apr;39(2):111-7. doi: 10.1016/j.diabet.2013.02.001. Epub 2013 Mar 15. Review.
•   Muchmore DB, Heinemann L, Tamborlane W, Wu XW, Fleming A
  Assessing rates of hypoglycemia as an end point in clinical trials. Diabetes Care. 2015 Oct;38(10):e160-1. doi: 10.2337/dc15-0808. Epub 2015 Aug 17.
•   Muretta JM, Mastick CC
  How insulin regulates glucose transport in adipocytes. Vitam Horm. 2009;80:245-86. doi: 10.1016/S0083-6729(08)00610-9. Review.
•   Nandish S, Wyatt J, Bailon O, Smith M, Oliveros R, Chilton R
  Implementing cardiovascular risk reduction in patients with cardiovascular disease and diabetes mellitus. Am J Cardiol. 2011 Aug 2;108(3 Suppl):42B-51B. doi: 10.1016/j.amjcard.2011.03.015. Review.
•   ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S
  Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.
•   Østerberg O, Erichsen L, Ingwersen SH, Plum A, Poulsen HE, Vicini P
  Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. J Pharmacokinet Pharmacodyn. 2003 Jun;30(3):221-35.
•   Razavi Nematollahi L, Kitabchi AE, Stentz FB, Wan JY, Larijani BA, Tehrani MM, Gozashti MH, Omidfar K, Taheri E
  Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects. Metabolism. 2009 Apr;58(4):443-8. doi: 10.1016/j.metabol.2008.10.018. Erratum in: Metabolism. 2009 Jul;58(7):1046. Kitabchi, Abbas Eghbal [corrected to Kitabchi, Abbas E].
•   Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A
  Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005 Apr;28(4):950-5.
•   Sanders EJ, Harvey S
  Peptide hormones as developmental growth and differentiation factors. Dev Dyn. 2008 Jun;237(6):1537-52. doi: 10.1002/dvdy.21573. Review.
•   Scheen AJ
  New therapeutic approaches in type 2 diabetes. Acta Clin Belg. 2008 Nov-Dec;63(6):402-7. Review.
•   Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR, Rodriguez H, Rosenzweig J, Vigersky R
  Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013 May;36(5):1384-95. doi: 10.2337/dc12-2480. Epub 2013 Apr 15.
•   Singh P, Jain A, Kaur G
  Impact of hypoglycemia and diabetes on CNS: correlation of mitochondrial oxidative stress with DNA damage. Mol Cell Biochem. 2004 May;260(1-2):153-9.
•   Somwar R, Sweeney G, Ramlal T, Klip A
  Stimulation of glucose and amino acid transport and activation of the insulin signaling pathways by insulin lispro in L6 skeletal muscle cells. Clin Ther. 1998 Jan-Feb;20(1):125-40.
•   Steensgaard DB, Schluckebier G, Strauss HM, Norrman M, Thomsen JK, Friderichsen AV, Havelund S, Jonassen I
  Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec. Biochemistry. 2013 Jan 15;52(2):295-309. doi: 10.1021/bi3008609. Epub 2013 Jan 3.
•   Varvarovská J, Racek J, Stetina R, Sýkora J, Pomahacová R, Rusavý Z, Lacigová S, Trefil L, Siala K, Stozický F
  Aspects of oxidative stress in children with type 1 diabetes mellitus. Biomed Pharmacother. 2004 Dec;58(10):539-45.
•   Vora J, Christensen T, Rana A, Bain SC
  Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther. 2014 Dec;5(2):435-46. doi: 10.1007/s13300-014-0076-9. Epub 2014 Aug 1.
•   Wang J, Alexanian A, Ying R, Kizhakekuttu TJ, Dharmashankar K, Vasquez-Vivar J, Gutterman DD, Widlansky ME
  Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: role for AMP kinase. Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):712-20. doi: 10.1161/ATVBAHA.111.227389. Epub 2011 Dec 29.
•   Weight gain associated with intensive therapy in the diabetes control and complications trial
  The DCCT Research Group. Diabetes Care. 1988 Jul-Aug;11(7):567-73.
•   Wolff SP, Dean RT
  Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J. 1987 Jul 1;245(1):243-50.
•   Wright RJ, Frier BM
  Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev. 2008 Jul-Aug;24(5):353-63. doi: 10.1002/dmrr.865. Review.
•   Zib I, Raskin P
  Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab. 2006 Nov;8(6):611-20. Review.
•   Ziegler D, Buchholz S, Sohr C, Nourooz-Zadeh J, Roden M
  Oxidative stress predicts progression of peripheral and cardiac autonomic nerve dysfunction over 6 years in diabetic patients. Acta Diabetol. 2015 Feb;52(1):65-72. doi: 10.1007/s00592-014-0601-3. Epub 2014 Jun 5.

Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. Clinical Trial of Low Level of Intervention. (Ineox Study)

Details for clinical trial NCT03328845